Jennifer J Clark

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Doriano Fabbro, Peter Marynen, Pascal Furet, 2004, Cancer Research.

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Andrea Califano, Stephen S Roberts, Ryma Benayed, 2019, Cancer discovery.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Doriano Fabbro, D. Fabbro, J. Griffin, 2005, Blood.